2023
ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
Chen J, Jacot W, Cortés J, Krop I, Dent S, Harbeck N, De Laurentiis M, Diéras V, Im Y, Stout T, Schimmoller F, Savage H, Hutchinson K, Wilson T. ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes. Molecular Oncology 2023, 17: 2000-2016. PMID: 36892268, PMCID: PMC10552898, DOI: 10.1002/1878-0261.13416.Peer-Reviewed Original ResearchConceptsProgression-free survivalBreast cancerShorter progression-free survivalNeurofibromin 1Advanced breast cancerBreast cancer patientsP53 pathway genesPI3K inhibitorsPI3K inhibitionBaseline ctDNAEndocrine therapyClinical outcomesCancer patientsEstrogen receptorCatalytic subunit alphaTumor DNATaselisibK inhibitorsK inhibitionPI3KOutcomesCancerAlterationsGenomic landscapeProtein p53
2009
Mechanisms of trastuzumab resistance in breast cancer.
Tolaney SM, Krop IE. Mechanisms of trastuzumab resistance in breast cancer. Anti-Cancer Agents In Medicinal Chemistry 2009, 9: 348-55. PMID: 19275526, DOI: 10.2174/1871520610909030348.Peer-Reviewed Original ResearchConceptsBreast cancerTrastuzumab resistanceHER2-positive metastatic breast cancerHER2-positive breast cancerDevelopment of trastuzumabOutcomes of patientsTrastuzumab-based therapyMetastatic breast cancerInvasive breast cancerHER2/neu geneHumanized monoclonal antibodyPoor patient outcomesNovel therapeutic agentsPatient outcomesTherapeutic agentsPatientsTrastuzumabCancerMonoclonal antibodiesAntitumor activityNeu genePotential mechanismsOutcomesSignificant improvementExtracellular domain